JP2024000504A5 - - Google Patents

Info

Publication number
JP2024000504A5
JP2024000504A5 JP2023083544A JP2023083544A JP2024000504A5 JP 2024000504 A5 JP2024000504 A5 JP 2024000504A5 JP 2023083544 A JP2023083544 A JP 2023083544A JP 2023083544 A JP2023083544 A JP 2023083544A JP 2024000504 A5 JP2024000504 A5 JP 2024000504A5
Authority
JP
Japan
Prior art keywords
hsa
mir
hmgb1
hmgb1 expression
expression inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023083544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024000504A (ja
Filing date
Publication date
Application filed filed Critical
Priority to US18/877,773 priority Critical patent/US20250382614A1/en
Priority to CN202380046684.6A priority patent/CN119365204A/zh
Priority to PCT/JP2023/021640 priority patent/WO2023248844A1/ja
Priority to EP23827030.0A priority patent/EP4541358A1/en
Publication of JP2024000504A publication Critical patent/JP2024000504A/ja
Publication of JP2024000504A5 publication Critical patent/JP2024000504A5/ja
Pending legal-status Critical Current

Links

JP2023083544A 2022-06-20 2023-05-20 Hmgb1の発現制御剤;急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法 Pending JP2024000504A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US18/877,773 US20250382614A1 (en) 2022-06-20 2023-06-12 Hmgb1 expression regulator, prophylactic agent or therapeutic agent for acute lung injury, acute respiratory distress syndrome, or sepsis, or method of ameliorating same
CN202380046684.6A CN119365204A (zh) 2022-06-20 2023-06-12 Hmgb1的表达调控剂;急性肺损伤、急性呼吸窘迫综合征或败血症的预防药或治疗药,或它们的改善方法
PCT/JP2023/021640 WO2023248844A1 (ja) 2022-06-20 2023-06-12 Hmgb1の発現制御剤;急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法
EP23827030.0A EP4541358A1 (en) 2022-06-20 2023-06-12 Hmgb1 expression suppressor, prophylactic or therapeutic drug for acute lung injury, acute respiratory distress syndrome or sepsis, and method for ameliorating such disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022098639 2022-06-20
JP2022098639 2022-06-20

Publications (2)

Publication Number Publication Date
JP2024000504A JP2024000504A (ja) 2024-01-05
JP2024000504A5 true JP2024000504A5 (cg-RX-API-DMAC7.html) 2026-05-27

Family

ID=89384628

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023083544A Pending JP2024000504A (ja) 2022-06-20 2023-05-20 Hmgb1の発現制御剤;急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法
JP2023083545A Pending JP2024000505A (ja) 2022-06-20 2023-05-20 Ptx3の発現制御剤;関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023083545A Pending JP2024000505A (ja) 2022-06-20 2023-05-20 Ptx3の発現制御剤;関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法

Country Status (1)

Country Link
JP (2) JP2024000504A (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025170079A1 (ja) * 2024-02-09 2025-08-14 セルファクター株式会社 慢性炎症を抑制するための医薬組成物
WO2025181030A1 (en) * 2024-02-26 2025-09-04 Fundació Institut D'investigació I Innovació Parc Taulí Therapy for inflammatory lung diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126176A1 (ja) * 2013-02-13 2014-08-21 国立大学法人名古屋大学 炎症性疾患の予防又は治療用組成物